{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:32:36Z","timestamp":1786422756528,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T00:00:00Z","timestamp":1512518400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Nemours Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00431-017-3051-4","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T20:43:50Z","timestamp":1512506630000},"page":"69-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment"],"prefix":"10.1007","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0950-3347","authenticated-orcid":false,"given":"James P.","family":"Franciosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Mougey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto A.","family":"Gomez Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa L.","family":"Creech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Corao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"issue":"5","key":"3051_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/j.1365-2125.2008.03104.x","volume":"65","author":"RM Baldwin","year":"2008","unstructured":"Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65(5):767\u2013774. \nhttps:\/\/doi.org\/10.1111\/j.1365-2125.2008.03104.x","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3051_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MPG.0b013e3182844705","volume":"56","author":"K Benkov","year":"2013","unstructured":"Benkov K, Lu Y, Patel A, Rahhal R, Russell G, Teitelbaum J, NASPGHAN Committee on Inflammatory Bowel Disease (2013) Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD. J Pediatr Gastroenterol Nutr 56(3):333\u2013340. \nhttps:\/\/doi.org\/10.1097\/MPG.0b013e3182844705","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"3051_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0361-090X(03)00103-X","volume":"27","author":"W Cao","year":"2003","unstructured":"Cao W, Hashibe M, Rao JY, Morgenstern H, Zhang ZF (2003) Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev 27(5):397\u2013404. \nhttps:\/\/doi.org\/10.1016\/S0361-090X(03)00103-X","journal-title":"Cancer Detect Prev"},{"issue":"2","key":"3051_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/gim.2016.87","volume":"19","author":"KE Caudle","year":"2016","unstructured":"Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV, Hoffman JM (2016) Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med 19(2):215\u2013223. \nhttps:\/\/doi.org\/10.1038\/gim.2016.87","journal-title":"Genet Med"},{"key":"3051_CR5","volume-title":"IBM SPSS statistics for Windows, Version 22.0","author":"Corp. I","year":"2013","unstructured":"Corp. I (2013) IBM SPSS statistics for Windows, Version 22.0. IBM Corp., Armonk"},{"issue":"1","key":"3051_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/tpj.2014.28","volume":"15","author":"JP Depta","year":"2015","unstructured":"Depta JP, Lenzini PA, Lanfear DE, Wang TY, Spertus JA, Bach RG, Cresci S (2015) Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J 15(1):20\u201325. \nhttps:\/\/doi.org\/10.1038\/tpj.2014.28","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"3051_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","volume":"41","author":"Z Desta","year":"2002","unstructured":"Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41(12):913\u2013958. \nhttps:\/\/doi.org\/10.2165\/00003088-200241120-00002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3051_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1053\/j.gastro.2006.08.018","volume":"131","author":"GW Falk","year":"2006","unstructured":"Falk GW, Fennerty MB, Rothstein RI (2006) AGA Institute medical position statement on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology 131(4):1313\u20131314. \nhttps:\/\/doi.org\/10.1053\/j.gastro.2006.08.018","journal-title":"Gastroenterology"},{"issue":"7","key":"3051_CR9","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1377\/hlthaff.2014.0127","volume":"33","author":"CB Forrest","year":"2014","unstructured":"Forrest CB, Margolis P, Seid M, Colletti RB (2014) PEDSnet: how a prototype pediatric learning health system is being expanded into a national network. Health Aff (Millwood) 33(7):1171\u20131177. \nhttps:\/\/doi.org\/10.1377\/hlthaff.2014.0127","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"3051_CR10","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/amiajnl-2014-002743","volume":"21","author":"CB Forrest","year":"2014","unstructured":"Forrest CB, Margolis PA, Bailey LC, Marsolo K, Del Beccaro MA, Finkelstein JA, Milov DE, Vieland VJ, Wolf BA, Yu FB, Kahn MG (2014) PEDSnet: a national pediatric learning health system. J Am Med Inform Assoc 21(4):602\u2013606. \nhttps:\/\/doi.org\/10.1136\/amiajnl-2014-002743","journal-title":"J Am Med Inform Assoc"},{"issue":"3","key":"3051_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1067\/mcp.2001.113959","volume":"69","author":"T Furuta","year":"2001","unstructured":"Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69(3):158\u2013168. \nhttps:\/\/doi.org\/10.1067\/mcp.2001.113959","journal-title":"Clin Pharmacol Ther"},{"issue":"5\u20136","key":"3051_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00228-005-0901-1","volume":"61","author":"B Gawronska-Szklarz","year":"2005","unstructured":"Gawronska-Szklarz B, Wrzesniewska J, Starzynska T, Pawlik A, Safranow K, Ferenc K et al (2005) Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 61(5\u20136):375\u2013379. \nhttps:\/\/doi.org\/10.1007\/s00228-005-0901-1","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3051_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00228-012-1252-3","volume":"68","author":"B Gawronska-Szklarz","year":"2012","unstructured":"Gawronska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M et al (2012) CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol 68(9):1267\u20131274. \nhttps:\/\/doi.org\/10.1007\/s00228-012-1252-3","journal-title":"Eur J Clin Pharmacol"},{"key":"3051_CR14","unstructured":"Genes-Drugs. CPIC website. 2017, \nhttps:\/\/cpicpgx.org\/genes-drugs\/\n\n. Accessed 20 July 2017"},{"issue":"5","key":"3051_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00228-011-1151-z","volume":"68","author":"E Gumus","year":"2012","unstructured":"Gumus E, Karaca O, Babaoglu MO, Baysoy G, Balamtekin N, Demir H, Uslu N, Bozkurt A, Yuce A, Yasar U (2012) Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol 68(5):629\u2013636. \nhttps:\/\/doi.org\/10.1007\/s00228-011-1151-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3051_CR16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2217\/pgs.11.4","volume":"12","author":"K Hagymasi","year":"2011","unstructured":"Hagymasi K, Mullner K, Herszenyi L, Tulassay Z (2011) Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 12(6):873\u2013888. \nhttps:\/\/doi.org\/10.2217\/pgs.11.4","journal-title":"Pharmacogenomics"},{"issue":"4","key":"3051_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/jama.2011.2035","volume":"307","author":"JT Holbrook","year":"2012","unstructured":"Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Writing Committee for the American Lung Association Asthma Clinical Research C et al (2012) Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA 307(4):373\u2013381. \nhttps:\/\/doi.org\/10.1001\/jama.2011.2035","journal-title":"JAMA"},{"issue":"9","key":"3051_CR18","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/archinternmed.2010.89","volume":"170","author":"MD Howell","year":"2010","unstructured":"Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170(9):784\u2013790. \nhttps:\/\/doi.org\/10.1001\/archinternmed.2010.89","journal-title":"Arch Intern Med"},{"issue":"5","key":"3051_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1365-2125.2007.03094.x","volume":"65","author":"NG Hunfeld","year":"2008","unstructured":"Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, Kuipers EJ, Geus WP (2008) Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 65(5):752\u2013760. \nhttps:\/\/doi.org\/10.1111\/j.1365-2125.2007.03094.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3051_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/jgh.13233","volume":"31","author":"H Ichikawa","year":"2016","unstructured":"Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T (2016) Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol 31(4):716\u2013726. \nhttps:\/\/doi.org\/10.1111\/jgh.13233","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"3051_CR21","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1097\/00005176-200311001-00011","volume":"37","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Winter HS (2003) Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr 37(Suppl 1):S52\u2013S59. \nhttps:\/\/doi.org\/10.1097\/00005176-200311001-00011","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"3051_CR22","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1124\/dmd.109.030601","volume":"38","author":"GL Kearns","year":"2010","unstructured":"Kearns GL, Leeder JS, Gaedigk A (2010) Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos 38(6):894\u2013897. \nhttps:\/\/doi.org\/10.1124\/dmd.109.030601","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"3051_CR23","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.2217\/pgs.14.103","volume":"15","author":"JJ Lima","year":"2014","unstructured":"Lima JJ, Franciosi JP (2014) Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. Pharmacogenomics 15(11):1405\u20131416. \nhttps:\/\/doi.org\/10.2217\/pgs.14.103","journal-title":"Pharmacogenomics"},{"issue":"3","key":"3051_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jpeds.2013.03.017","volume":"163","author":"JJ Lima","year":"2013","unstructured":"Lima JJ, Lang JE, Mougey EB, Blake KB, Gong Y, Holbrook JT, Wise RA, Teague WG (2013) Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr 163(3):686\u2013691. \nhttps:\/\/doi.org\/10.1016\/j.jpeds.2013.03.017","journal-title":"J Pediatr"},{"issue":"3","key":"3051_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","volume":"69","author":"A Li-Wan-Po","year":"2010","unstructured":"Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J (2010) Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 69(3):222\u2013230. \nhttps:\/\/doi.org\/10.1111\/j.1365-2125.2009.03578.x","journal-title":"Br J Clin Pharmacol"},{"key":"3051_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mex.2014.11.003","volume":"2","author":"MF Loayza","year":"2015","unstructured":"Loayza MF, Villavicencio FX, Santander SC, Baldeon M, Ponce LK, Salvador I et al (2015) Improved method for extraction and detection of Helicobacter pylori DNA in formalin-fixed paraffin embedded gastric biopsies using laser micro-dissection. MethodsX 2:1\u20137. \nhttps:\/\/doi.org\/10.1016\/j.mex.2014.11.003","journal-title":"MethodsX"},{"issue":"3","key":"3051_CR27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jpeds.2012.08.045","volume":"162","author":"C Loots","year":"2013","unstructured":"Loots C, van Herwaarden MY, Benninga MA, VanderZee DC, van Wijk MP, Omari TI (2013) Gastroesophageal reflux, esophageal function, gastric emptying, and the relationship to dysphagia before and after antireflux surgery in children. J Pediatr 162(3):566\u2013573 e2. \nhttps:\/\/doi.org\/10.1016\/j.jpeds.2012.08.045","journal-title":"J Pediatr"},{"issue":"2","key":"3051_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1155\/2014\/738203","volume":"28","author":"K Martin","year":"2014","unstructured":"Martin K, Deshaies C, Emil S (2014) Outcomes of pediatric laparoscopic fundoplication: a critical review of the literature. Can J Gastroenterol Hepatol 28(2):97\u2013102. \nhttps:\/\/doi.org\/10.1155\/2014\/738203","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"10","key":"3051_CR29","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1007\/s11605-011-1644-1","volume":"15","author":"FA Mauritz","year":"2011","unstructured":"Mauritz FA, van Herwaarden-Lindeboom MY, Stomp W, Zwaveling S, Fischer K, Houwen RH et al (2011) The effects and efficacy of antireflux surgery in children with gastroesophageal reflux disease: a systematic review. J Gastrointest Surg 15(10):1872\u20131878. \nhttps:\/\/doi.org\/10.1007\/s11605-011-1644-1","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"3051_CR30","doi-asserted-by":"publisher","first-page":"M179","DOI":"10.1136\/mp.49.3.M179","volume":"49","author":"K Morgan","year":"1996","unstructured":"Morgan K, Lam L, Kalsheker N (1996) A rapid and efficient method for DNA extraction from paraffin wax embedded tissue for PCR amplification. Clin Mol Pathol 49(3):M179\u2013M180. \nhttps:\/\/doi.org\/10.1136\/mp.49.3.M179","journal-title":"Clin Mol Pathol"},{"issue":"7","key":"3051_CR31","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/j.1572-0241.2006.00717.x","volume":"101","author":"S Padol","year":"2006","unstructured":"Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH (2006) The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 101(7):1467\u20131475. \nhttps:\/\/doi.org\/10.1111\/j.1572-0241.2006.00717.x","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"3051_CR32","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1542\/peds.2010-2719","volume":"127","author":"RJ Pol van der","year":"2011","unstructured":"van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA (2011) Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 127(5):925\u2013935. \nhttps:\/\/doi.org\/10.1542\/peds.2010-2719","journal-title":"Pediatrics"},{"issue":"1","key":"3051_CR33","first-page":"373","volume":"57","author":"JA Sandoval","year":"2010","unstructured":"Sandoval JA, Partrick DA (2010) Advances in the surgical management of gastroesophageal reflux. Adv Pediatr Infect Dis 57(1):373\u2013389","journal-title":"Adv Pediatr Infect Dis"},{"issue":"2","key":"3051_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamainternmed.2015.7927","volume":"176","author":"AJ Schoenfeld","year":"2016","unstructured":"Schoenfeld AJ, Grady D (2016) Adverse effects associated with proton pump inhibitors. JAMA Intern Med 176(2):172\u2013174. \nhttps:\/\/doi.org\/10.1001\/jamainternmed.2015.7927","journal-title":"JAMA Intern Med"},{"issue":"1","key":"3051_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103\u2013113. \nhttps:\/\/doi.org\/10.1016\/j.clpt.2005.10.002","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3051_CR36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIR.0b013e3181ee08ed","volume":"122","author":"DR Holmes Jr","year":"2010","unstructured":"Society for Cardiovascular A, Interventions, Society of Thoracic S, Writing Committee M, Holmes DR Jr, Dehmer GJ et al (2010) ACCF\/AHA clopidogrel clinical alert: approaches to the FDA \u201cboxed warning\u201d: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122(5):537\u2013557","journal-title":"Circulation"},{"issue":"1","key":"3051_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clpt.2006.03.007","volume":"80","author":"M Sugimoto","year":"2006","unstructured":"Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T (2006) Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clin Pharmacol Ther 80(1):41\u201350. \nhttps:\/\/doi.org\/10.1016\/j.clpt.2006.03.007","journal-title":"Clin Pharmacol Ther"},{"key":"3051_CR38","volume-title":"R: A language and environment for statistical computing","author":"Team RC","year":"2015","unstructured":"Team RC (2015) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna"},{"issue":"4","key":"3051_CR39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/MPG.0b013e3181b7f563","volume":"49","author":"Y Vandenplas","year":"2009","unstructured":"Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, Thomson M, Veereman-Wauters G, Wenzl TG, North American Society for Pediatric Gastroenterology Hepatology and Nutrition, European Society for Pediatric Gastroenterology Hepatology and Nutrition (2009) Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 49(4):498\u2013547. \nhttps:\/\/doi.org\/10.1097\/MPG.0b013e3181b7f563","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"3051_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40272-013-0012-x","volume":"15","author":"RM Ward","year":"2013","unstructured":"Ward RM, Kearns GL (2013) Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs 15(2):119\u2013131. \nhttps:\/\/doi.org\/10.1007\/s40272-013-0012-x","journal-title":"Paediatr Drugs"},{"issue":"1","key":"3051_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ajmg.c.31390","volume":"166C","author":"KW Weitzel","year":"2014","unstructured":"Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessl DR, Obeng AO, Staley BJ, Dong HJ, Allan RW, Liu JF, Cooper-Dehoff RM, Anderson RD, Conlon M, Clare-Salzler MJ, Nelson DR, Johnson JA (2014) Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet 166C(1):56\u201367. \nhttps:\/\/doi.org\/10.1002\/ajmg.c.31390","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"3051_CR42","doi-asserted-by":"publisher","unstructured":"Yi X, Han Z, Zhou Q, Cheng W, Lin J, Wang C (2016) Concomitant use of proton-pump inhibitors and clopidogrel increases the risk of adverse outcomes in patients with ischemic stroke carrying reduced-function CYP2C19*2. Clin Appl Thromb Hemost. \nhttps:\/\/doi.org\/10.1177\/1076029616669787","DOI":"10.1177\/1076029616669787"},{"issue":"6","key":"3051_CR43","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1523-5378.2008.00643.x","volume":"13","author":"F Zhao","year":"2008","unstructured":"Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G (2008) Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 13(6):532\u2013541. \nhttps:\/\/doi.org\/10.1111\/j.1523-5378.2008.00643.x","journal-title":"Helicobacter"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-017-3051-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-017-3051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-017-3051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T17:36:12Z","timestamp":1514828172000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-017-3051-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,6]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3051"],"URL":"https:\/\/doi.org\/10.1007\/s00431-017-3051-4","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,6]]}}}